Rein Therapeutics Terminates Material Agreement
Ticker: RNTX · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-agreement
TL;DR
Rein Therapeutics terminated a key deal, details TBD.
AI Summary
Rein Therapeutics, Inc. filed an 8-K on December 11, 2025, to report the termination of a material definitive agreement. The filing does not specify the other party to the agreement or the nature of the agreement, only that it is no longer in effect.
Why It Matters
The termination of a material definitive agreement can signal significant changes in a company's operations, partnerships, or financial arrangements, potentially impacting its future business trajectory.
Risk Assessment
Risk Level: medium — Termination of a material agreement can indicate underlying issues or strategic shifts that carry inherent business risks.
Key Players & Entities
- Rein Therapeutics, Inc. (company) — Registrant
- December 11, 2025 (date) — Date of report
- 12407 N. Mopac Expy., Suite 250, #390 Austin, Texas 78758 (address) — Principal executive offices
- Aileron Therapeutics, Inc. (company) — Former company name
FAQ
What specific material definitive agreement was terminated by Rein Therapeutics, Inc.?
The filing does not specify the name or nature of the material definitive agreement that was terminated.
Who was the other party to the terminated material definitive agreement?
The filing does not disclose the identity of the other party involved in the terminated agreement.
What is the effective date of the termination of the material definitive agreement?
The filing reports the termination as of December 11, 2025, which is also the date of the report.
Does the 8-K filing provide any details on the reasons for the termination?
No, the filing only states that a material definitive agreement has been terminated and does not provide reasons for the termination.
What was Rein Therapeutics, Inc.'s former name?
Rein Therapeutics, Inc. was formerly known as Aileron Therapeutics, Inc., with a name change effective March 29, 2024.
Filing Stats: 461 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-12-11 17:20:53
Key Financial Figures
- $3 million — ville. The Company had taken a total of $3 million of advances under the PPA, the most rec
Filing Documents
- d783815d8k.htm (8-K) — 22KB
- 0001193125-25-316225.txt ( ) — 136KB
- rntx-20251211.xsd (EX-101.SCH) — 3KB
- rntx-20251211_lab.xml (EX-101.LAB) — 18KB
- rntx-20251211_pre.xml (EX-101.PRE) — 11KB
- d783815d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REIN THERAPEUTICS, INC. Dated: December 11, 2025 /s/ Brian Windsor Brian Windsor, Ph.D., President and Chief Executive Officer